Pre-made Pinatuzumab biosimilar ( Whole mAb ADC, anti-CD22 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-444
Anti-CD22 therapeutic antibody (Pre-made Pinatuzumab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pinatuzumab vedotin (DCDT2980S, FCU2703) is an anti-CD22 antibody-drug conjugate (ADC) developed by Genentech/ Hoffmann-La Roche for the treatment of diffuse large B-cell lymphoma (DLBCL). ... Pinatuzumab vedotin has proved its efficacy in inducing a complete tumor regression in xenograft lymphoma models.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD22 therapeutic antibody (Pre-made Pinatuzumab biosimilar,Whole mAb ADC)|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||6and:HL|
|95-98% SI Structure||None|
|Conditions Discontinued||Chronic lymphocytic leukaemia;Diffuse large B cell lymphoma;Non-Hodgkin's lymphoma|